Laurus Labs Limited

Laurus Labs Limited

Laurus Labs Limited has been assigned an ESG rating of 82.6 by CARE ESG Ratings Limited, indicating a leadership position in managing ESG risk.

Laurus Labs Limited

Laurus Labs Limited has informed the Exchange about an update on its equity investment in KRKA Pharma Private Limited. The company has invested INR 1,078,000,000/- and acquired 107,800,000 equity shares of KRKA at face value of INR 10/- each, aggregating to an amount of INR 1,078,000,000/-. The total holding of the Company in KRKA is 262,150,000 equity shares of INR 10/- each, and the percentage of shareholding by the Company shall remain same at 49%.

Laurus Labs Limited

Laurus Labs Limited has scheduled a conference call to discuss its Q2 & H1 FY27 results on October 29, 2026, at 5:00 pm IST.

Laurus Labs Limited

Laurus Labs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.

Laurus Labs Limited

Laurus Labs Limited has informed the Exchange about an update on its acquisition of equity shares in Kurnool Renewables Private Limited, an associate company. The company has invested INR 12,09,60,500 and acquired 1,20,96,050 equity shares at face value of INR 10 each. The total holding of the company in KRPL is now 2,11,68,000 equity shares, with a shareholding percentage remaining at 26%.

Laurus Labs Limited

Laurus Labs Limited has closed its trading window for dealing in its securities from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half-year ending September 30, 2026.

Laurus Labs Limited

Laurus Labs Limited has informed the Exchange about Investor Presentation, which includes information on the company's strong operational performance, leading manufacturing platform, and accelerated CAPEX to meet growing demand. The presentation highlights the company's revenue growth, EBITDA margin, and net debt/EBITDA ratio.

Laurus Labs Limited

Laurus Labs Limited has informed the Exchange about its schedule of analyst/institutional investor meetings, including a Goldman Sachs Global Healthcare CDMO Day in Singapore on September 22-24, 2026.

Laurus Labs Limited

Laurus Labs Limited has informed the Exchange about a scheduled analyst/institutional investor meeting on September 17, 2026, in Hyderabad, organized by ICICI Securities.

Laurus Labs Limited

Laurus Labs Limited has informed the Exchange about Schedule of meet for an Investor Conference on September 07, 2026, at Hyderabad. The meeting is subject to change due to exigencies and no unpublished price sensitive information will be shared.

Laurus Labs Limited

Laurus Labs Limited has informed the Exchange about the schedule of an analyst/institutional investor meeting, to be held on August 19, 2026, at the 22nd Annual Global Investor Conference in Mumbai.

Laurus Labs Limited

Laurus Labs Limited has informed the Exchange about Intimation of ESG Score given by NSE Sustainability Ratings and Analytics Limited. The company has been assigned an Environmental, Social, and Governance Score (ESG Score) of 63 out of 100 for FY 2026.

Laurus Labs Limited

Laurus Labs Limited has hosted a Q1 FY27 earnings conference call, discussing strong growth momentum, with revenue of INR2,026 crores, a 29% growth, and EBITDA margins expanding to 31.8%. The company has also signed a development and commercial agreement with Aarvik Therapeutics for 2 ADC molecules and onboarded a big pharma client.

Laurus Labs Limited

Laurus Labs Limited has informed the Exchange about the allotment of 62,635 equity shares to eligible employees on exercise of ESOPs under Laurus Employees Stock Option Scheme 2016, Laurus Employees Stock Option Scheme 2018, and Laurus Labs Employees Stock Option Scheme 2021.

Laurus Labs Limited

Laurus Labs Limited has informed the Exchange about an update on the Composite Scheme of Arrangement. The Hon'ble National Company Law Tribunal, Amravati Special Branch has directed the Petitioner Companies to serve the notice of the hearing of the Petition in Form No. CAA-3 to concerned authorities/regulators and other stakeholders. The next date of hearing is September 10, 2026.

Laurus Labs Limited

Laurus Labs Limited has informed the Exchange about the publication of unaudited financial results for the quarter ended June 30, 2026, in compliance with Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Laurus Labs Limited

Laurus Labs Limited has informed the Exchange about the link of the recording of the Q1 FY27 Results Conference Call hosted on July 24, 2026.

Laurus Labs Limited

Laurus Labs Limited has announced its Q1 FY27 results, with revenue at ₹ 2,026 Cr, representing 29% growth, and EBITDA at ₹ 644 Cr, representing 66% growth. The company has achieved strong operating performance despite macroeconomic volatility, with improved capacity utilization and operating leverage.

Laurus Labs Limited

Laurus Labs Limited has informed the Exchange about Presentation to the Investors/Analysts on the Standalone and Consolidated Unaudited Financial Results for the quarter ended June 30, 2026. The presentation is for the Investors/Analysts call scheduled on July 24, 2026.

Laurus Labs Limited

Laurus Labs Limited has informed the Exchange regarding Change in Director(s) of the company. Dr. Rajesh Koshy Chandy has retired as an Independent Director with effect from July 26, 2026.